MWA CONSULTING, INC.
  • Home
  • About MWA
  • Consulting Services
  • Industry News
  • Webinars & Podcasts
  • Consulting Opportunities
  • Contact
  • Privacy Policy
Select Page

Inspection of Injectable Products for Visible Particulates: Draft Guidance for Industry

Dec 22, 2021

FROM THE INTRODUCTION: Visible particulates in injectable products can jeopardize patient safety. This guidance addresses the development and implementation of a holistic, risk-based approach to visible particulate control that incorporates product development,...


Stay current with FDA regulatory news and compliance trends!

Follow MWA on LinkedIn:

Recent Posts

  • FDA Issued Guidance to Help Identify Suspect and Illegitimate Product in the U.S. Pharmaceutical Distribution Supply Chain
  • FDA Released Draft Guidance on the Use of Electronic Systems, Records, and Signatures in Clinical Investigations
  • FDA Released Recommendations that Assist in the Development of Monoclonal Antibodies (mAbs) and other Therapeutic Proteins
  • New Guidance Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products from FDA
  • FDA Published New Draft Guidance for M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms

Designed by Elegant Themes | Powered by WordPress